8-K: Dyadic International Reports Strong 2024 Revenue Growth Driven by Licensing and Milestone Payments

Dyadic International announces its 2024 financial results, highlighting revenue growth, progress in commercializing its protein production platforms, and advancements in animal and human health applications.

Summary

• Dyadic International reported its financial results for the year ended December 31, 2024.
• The company saw an increase in total revenue to approximately $3.495 million, compared to $2.899 million in 2023.
• This increase was driven by $1.9 million in milestone and license revenue.
• Dyadic received up to $7.5 million in grants from CEPI and the Gates Foundation to accelerate the C1 platform development.
• The company's cash and investment-grade securities totaled $9.3 million as of December 31, 2024.
• The net loss for the year was approximately $5.809 million, or $(0.20) per share, compared to a net loss of $6.795 million, or $(0.24) per share, for 2023.
• Dyadic is progressing towards commercial launch of Human Serum Albumin in Q2 2025 in partnership with Proliant.
• A third milestone payment is anticipated in Q3 2025 related to productivity improvements with Proliant.
• Sampling efforts for recombinant FGF products are expected to begin in Q2 2025.
• Sampling efforts for human lactoferrin are expected to begin in 2H 2025.
• Commercialization efforts are ongoing for a recombinant dairy enzyme with an anticipated launch in late 2025.
• Development and optimization are ongoing for four additional enzymes, with results expected by the end of 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with increased revenue, significant grant funding, and progress in product development. However, the company is still operating at a net loss, which tempers the overall sentiment.

Positives

• Revenue increased by approximately $596,000 year-over-year, driven by licensing and milestone payments.
• The company secured significant grant funding from CEPI and the Gates Foundation, totaling up to $7.5 million.
• Cash position improved to $9.3 million, providing financial stability.
• Loss from operations decreased from $8.230 million to $5.901 million.
• Net loss per share improved from $(0.24) to $(0.20).
• The company is progressing towards commercial launch of several products, including Human Serum Albumin and DNase1.
• The C1 platform is being advanced through a $4.5 million CEPI grant to Fondazione Biotecnopolo di Siena (FBS) to accelerate recombinant protein vaccine development and manufacturing.
• The company was awarded a $3 million grant from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus (RSV) and malaria.

Negatives

• The company continues to operate at a net loss, reporting a loss of $5.809 million for the year.
• General and administrative expenses increased to approximately $6.135 million compared to $5.817 million in 2023.
• Other income decreased due to increased interest expenses and the absence of a gain on the sale of Alphazyme, LLC, which occurred in 2023.
• The company has convertible notes outstanding, which incur interest expenses.

Risks

• The company's success depends on market and regulatory acceptance of its microbial protein production platforms.
• Competition from alternative technologies could hinder the company's growth.
• The company relies on third parties for various aspects of its operations, which could pose risks.
• Changes in global economic and financial conditions could impact the company's performance.
• Intellectual property risks could affect the company's competitive advantage.
• The company has a history of net losses.

Future Outlook

Dyadic remains committed to expanding the reach of its C1 and Dapibus platforms across alternative proteins, and human and animal health, with a growing network of partnerships and increased funding support.

Management Comments

• We believe our strong 2024 performance and achievements underscore Dyadics commitment to leveraging our advanced microbial protein production platforms to accelerate commercialization and drive sustained revenue in high-value alternative protein applications, said Mark Emalfarb, Dyadics Chief Executive Officer.
• Our strategic focus on developing products in profitable non-pharmaceutical market segments has resulted in key milestones, including $1.9 million in revenue from our cell culture media and non-animal dairy segments.
• We continue to expand our biopharmaceutical capabilities through collaborations with globally recognized organizations, including the Coalition for Epidemic Preparedness Innovations, Fondazione Biotecnopolo di Siena, and the Bill & Melinda Gates Foundation.
• With a growing network of partnerships and increased funding support, we believe we are well-positioned to drive innovation, enhance global accessibility, and reduce costs in manufacturing of recombinant proteins while delivering sustained value for our investors and stakeholders, Mr. Emalfarb concluded.

Industry Context

Dyadic's focus on microbial protein production platforms aligns with the growing demand for efficient and cost-effective manufacturing of proteins for various applications, including vaccines, therapeutics, and alternative proteins. The collaborations with CEPI and the Gates Foundation highlight the company's potential to contribute to global health initiatives.

Comparison to Industry Standards

• Dyadic's C1 platform aims to compete with traditional protein production methods, such as those used by companies like Genentech (Roche) and Amgen, by offering potentially lower production costs and faster development times.
• The company's focus on alternative proteins places it in competition with companies like Perfect Day and Impossible Foods, which are also developing non-animal derived products.
• The grants from CEPI and the Gates Foundation are comparable to funding received by other biotechnology companies working on vaccine and antibody development, such as Moderna and BioNTech.
• The development of recombinant proteins for cell culture media puts Dyadic in competition with companies like Thermo Fisher Scientific and Merck KGaA, which are major suppliers of cell culture products.

Stakeholder Impact

• Shareholders may benefit from the increased revenue and potential for future growth.
• Employees may benefit from the company's progress and expansion.
• Customers may benefit from the availability of new and improved products.
• The company's collaborations with CEPI and the Gates Foundation could contribute to global health initiatives.

Next Steps

• Progress towards commercial launch of Human Serum Albumin in Q2 2025.
• Achieve a third milestone payment in Q3 2025 related to productivity improvements with Proliant.
• Begin sampling efforts for recombinant FGF products in Q2 2025.
• Begin sampling efforts for human lactoferrin in 2H 2025.
• Launch a recombinant dairy enzyme in late 2025.
• Obtain results for the development and optimization of four additional enzymes by the end of 2025.
• Continue pre-commercial research and validation efforts to support potential strategic partnerships and licensing opportunities for C1 produced Ferritin Nanoparticle Vaccines.

Key Dates

Keywords

Dyadic International, C1 platform, Dapibus, protein production, vaccines, therapeutics, biotechnology, financial results, licensing revenue, milestone payments, CEPI, Gates Foundation, human health, animal health